EUVIMEDEUVIMED entdecken
Crossref

Discovery of Dual A2A/A2B Adenosine Receptor Antagonist and Clinical Candidate INCB106385

Chao Qi, Matthew S McCammant iD, Yong Li, Wenyu Zhu, Zhiyong Yu, Peter Carlsen, Heeoon Han, Le Zhao, Fenglei Zhang, Taisheng Huang, Pei Gan, Dingquan Qian und 17 weitere

Journal of Medicinal Chemistry · 11.06.2026 · 69 (11) · 13899-13918

DOI: 10.1021/acs.jmedchem.6c00964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.05.2026. Verfasst von Chao Qi und 28 weiteren Autor:innen. Beteiligte Einrichtung: Incyte Research Institute, Incyte Corporation, Wilmington, Delaware19803, United States. Hauptthemen laut MEDLINE: Adenosine A2 Receptor Antagonists, Antineoplastic Agents, Drug Discovery, Receptor, Adenosine A2A. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Incyte.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Suppression of immune checkpoint pathways enables tumor cells to take over immunoregulatory functions, promoting cell growth and proliferation. Elevated adenosine production in the tumor microenvironment suppresses immune checkpoint control through activation of A2A adenosine receptors on immune cells. While A2A antagonists originally developed for CNS indications have entered oncology, their potency may be insufficient to challenge locally high adenosine concentrations within the tumor microenvironment for receptor occupancy. Here, we describe the discovery of INCB106385 (36), a potent dual A2A/A2B antagonist identified from in-house screening efforts. Compound 36 exhibits high potency at both receptors, favorable drug-like properties, and limited CNS penetration. In preclinical studies, it demonstrated robust pharmacokinetics across species and significant efficacy in a multiday CT26 mouse colon carcinoma model. These findings supported the advancement of INCB106385 into Phase 1 clinical trials (NCT04580485, NCT04989387) for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine A2 Receptor AntagonistsAntineoplastic AgentsDrug DiscoveryReceptor, Adenosine A2AReceptor, Adenosine A2BAnimalsHumansMiceColonic NeoplasmsStructure-Activity RelationshipClinical Trials, Phase I as Topic

Substanzen

Adenosine A2 Receptor AntagonistsAntineoplastic AgentsReceptor, Adenosine A2AReceptor, Adenosine A2B

Autor:innen und Institutionen

  • Incyte Research Institute, Incyte Corporation, Wilmington, Delaware19803, United States.

ORCID-Profile: Matthew S McCammant

Förderung

  • Incyte

Zitieren

APA

Qi, C., McCammant, M. S., Li, Y., Zhu, W., Yu, Z., Carlsen, P., Han, H., Zhao, L., Zhang, F., Huang, T., Gan, P., Qian, D., Hoang, G., He, C., Mei, S., Harris, J. J., Gallion, A., Hansbury, M., Mason, J., …, & Wang, X. (2026). Discovery of Dual A2A/A2B Adenosine Receptor Antagonist and Clinical Candidate INCB106385. Journal of Medicinal Chemistry, 69(11), 13899-13918. https://doi.org/10.1021/acs.jmedchem.6c00964

Vancouver

Qi C, McCammant MS, Li Y, Zhu W, Yu Z, Carlsen P, et al. Discovery of Dual A2A/A2B Adenosine Receptor Antagonist and Clinical Candidate INCB106385. Journal of Medicinal Chemistry. 2026;69(11):13899-13918. doi:10.1021/acs.jmedchem.6c00964

BibTeX
@article{Qi2026,
  author = {Qi, Chao and McCammant, Matthew S and Li, Yong and Zhu, Wenyu and Yu, Zhiyong and Carlsen, Peter and Han, Heeoon and Zhao, Le and Zhang, Fenglei and Huang, Taisheng and Gan, Pei and Qian, Dingquan and Hoang, Gia and He, Chunhong and Mei, Song and Harris, Jennifer J and Gallion, Alexandra and Hansbury, Michael and Mason, Jennifer and Stump, Kristine and Kurzeja-Lipinski, Kerri and DiRamio, Angela and Covington, Maryanne and Koblish, Holly and Diamond, Sharon and Wang, Hui and Scherle, Peggy and Yao, Wenqing and Wang, Xiaozhao},
  title = {Discovery of Dual A2A/A2B Adenosine Receptor Antagonist and Clinical Candidate INCB106385},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {11},
  pages = {13899--13918},
  doi = {10.1021/acs.jmedchem.6c00964}
}
Kostenlos starten →